DE69124534D1 - Katecholderivate, deren physiologisch unbedenkliche Salze, Ester und deren Verwendung bei der Behandlung von durch Lipidperoxidation verursachten Gewebeschäden - Google Patents

Katecholderivate, deren physiologisch unbedenkliche Salze, Ester und deren Verwendung bei der Behandlung von durch Lipidperoxidation verursachten Gewebeschäden

Info

Publication number
DE69124534D1
DE69124534D1 DE69124534T DE69124534T DE69124534D1 DE 69124534 D1 DE69124534 D1 DE 69124534D1 DE 69124534 T DE69124534 T DE 69124534T DE 69124534 T DE69124534 T DE 69124534T DE 69124534 D1 DE69124534 D1 DE 69124534D1
Authority
DE
Germany
Prior art keywords
treatment
tissue damage
lipid peroxidation
esters
acceptable salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69124534T
Other languages
English (en)
Other versions
DE69124534T2 (de
Inventor
Tapio Juhani Korkolainen
Erkki Aarne Olavi Nissinen
Reijo Johannes Backstrom
Aino Kyllikki Pippuri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Yhtyma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtyma Oy filed Critical Orion Yhtyma Oy
Publication of DE69124534D1 publication Critical patent/DE69124534D1/de
Application granted granted Critical
Publication of DE69124534T2 publication Critical patent/DE69124534T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/53Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and hydroxy groups bound to the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • A61K31/06Phenols the aromatic ring being substituted by nitro groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/13Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
    • C07C205/26Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups and being further substituted by halogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46Friedel-Crafts reactions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/24Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C07C49/245Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings
    • C07C49/248Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings having unsaturation outside the aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/527Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
    • C07C49/583Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing —CHO groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69124534T 1990-02-27 1991-02-27 Katecholderivate, deren physiologisch unbedenkliche Salze, Ester und deren Verwendung bei der Behandlung von durch Lipidperoxidation verursachten Gewebeschäden Expired - Fee Related DE69124534T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909004348A GB9004348D0 (en) 1990-02-27 1990-02-27 New use of catechol derivatives and their physiologically acceptable salts and esters

Publications (2)

Publication Number Publication Date
DE69124534D1 true DE69124534D1 (de) 1997-03-20
DE69124534T2 DE69124534T2 (de) 1997-07-03

Family

ID=10671658

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69124534T Expired - Fee Related DE69124534T2 (de) 1990-02-27 1991-02-27 Katecholderivate, deren physiologisch unbedenkliche Salze, Ester und deren Verwendung bei der Behandlung von durch Lipidperoxidation verursachten Gewebeschäden

Country Status (5)

Country Link
EP (1) EP0444899B1 (de)
JP (1) JP3157846B2 (de)
AT (1) ATE148626T1 (de)
DE (1) DE69124534T2 (de)
GB (1) GB9004348D0 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107736A (en) * 1993-11-24 2001-01-11 Yissum Res Dev Co Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases
KR100424392B1 (ko) * 2001-07-10 2004-03-24 한국화학연구원 믹소첼린-에이를 유효성분으로 하는 항산화 및 항암용약학 조성물
BRPI0910839A2 (pt) * 2008-04-30 2015-07-28 Nestec Sa Produtos contendo, e usos de, ácidos fenólicos descarboxilados derivados de ácidos clorogênicos de café
WO2012147099A1 (en) 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
US10071069B2 (en) 2014-09-04 2018-09-11 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof
KR20200136008A (ko) 2018-03-23 2020-12-04 롭서 파마슈티컬스 악티에볼라그 신경퇴행성 장애의 치료를 위한 약제학적 조성물의 연속 투여
CN113304129B (zh) * 2021-06-16 2022-11-08 温州医科大学附属第二医院(温州医科大学附属育英儿童医院) 单烯酮类单羰基姜黄素类似物在制备抗氧化药物的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4618627A (en) * 1983-05-13 1986-10-21 Yamanouchi Pharmaceutical Co., Ltd. Catechol derivatives and pharmaceutical compositions thereof for inhibiting anaphylaxis (SRS-A)
JPS6212757A (ja) * 1985-07-10 1987-01-21 Yoshitomi Pharmaceut Ind Ltd 桂皮酸アミド誘導体
YU213587A (en) * 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
MTP1031B (en) * 1987-12-24 1990-10-04 Orion Yhtymae Oy New use of cathecol-o-methyl transferase (comt) inhibitors and their physiologically acceptable salts and esters
US5070089A (en) * 1988-01-26 1991-12-03 Nippon Chemiphar Co., Ltd. Therapeutic agent for liver disease and piperazine derivatives
JPH01213276A (ja) * 1988-02-19 1989-08-28 Takeda Chem Ind Ltd ベンゾフラン透導体

Also Published As

Publication number Publication date
JPH04211627A (ja) 1992-08-03
EP0444899A3 (en) 1992-11-25
GB9004348D0 (en) 1990-04-25
EP0444899B1 (de) 1997-02-05
JP3157846B2 (ja) 2001-04-16
EP0444899A2 (de) 1991-09-04
DE69124534T2 (de) 1997-07-03
ATE148626T1 (de) 1997-02-15

Similar Documents

Publication Publication Date Title
DE3850109D1 (de) 13-trans-retinsäureester.
ES2162942T3 (es) Nuevos derivados de acidos carboxilicos, su obtencion y empleo.
ATE290867T1 (de) Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten
ATE217883T1 (de) Pentapeptid-amide und -ester, die menslichen krebs hemmen
MX9101869A (es) Ciclosporinas, composicion farmaceutica que las contiene y procedimiento para la produccion de las mismas
ATE135215T1 (de) Verwendung von rapamycin, dessen derivaten und prodrugs zur herstellung eines arzneimittels zur hemmung der transplantatabstossung bei säugetieren
DE3684409D1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose.
DE59309649D1 (de) Substituierte Cyclohexan-Derivate zur Behandlung von Krankheiten
ATE123944T1 (de) Verwendung von trifluormethylphenyl- tetrahydropyridinen zur herstellung von arzneimitteln zur behandlung anxio-depressiver erkrankungen.
DE69635670D1 (de) Threitol-buttersäureester-enthaltende zusammensetzungen und ihre verwendung
DE69124534D1 (de) Katecholderivate, deren physiologisch unbedenkliche Salze, Ester und deren Verwendung bei der Behandlung von durch Lipidperoxidation verursachten Gewebeschäden
NO892338D0 (no) Middel for insekt- og middbekjempelse.
DE59202618D1 (de) BIOTENSIDE ESTER MIT VITAMIN-D-VERBINDUNGEN; IHRE HERSTELLUNG UND AUFARBEITUNG ZU SPONTAN DISPERGIERBAREN kONZENTRATEN, SOWIE IHRE VERWENDUNG ZUR BEHANDLUNG VON TUMOREN.
ATE183088T1 (de) Arzneimittel zur behandlung von hauterkrankungen
ATE82850T1 (de) Verwendung von 2-pyrimidinyl-1-piperazinderivaten.
ATE110714T1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
EA199900363A1 (ru) Новые производные пентаэритрита, их получение и применение, а также промежуточные продукты для их синтеза
ATE99687T1 (de) Strobilurinderivate, ihre herstellung und verwendung.
ES2054790T3 (es) Compuestos que tienen actividad cardiovascular.
DE69200948T2 (de) Verwendung von Benzimidazolin-2-oxo-1-Carbonsäurederivaten bei der Behandlung organischer Gehirnerkrankungen.
ATE162195T1 (de) 4-hydroxy-phenyl-beta-d-glukose-monoester, verfahren zur ihrer herstellung und ihre verwendung in der kosmetik, der pharmazie, als zahnpflegemitteln und lebensmitteln
ES2098030T3 (es) Nuevos agentes cardioprotectores.
MX9304283A (es) Derivados de tiadiazinona, procedimiento para su preparacion y preparacion farmaceutica que los con tienen.
BG100367A (en) The use of esters of n-alkylated, 1,4-dihydropyrimidinedicarboxylic acids as medicamentous forms
ATE30032T1 (de) N-acylderivate von dipeptiden, ihre herstellung und verwendung bei der therapie von krankheiten und mittel dafuer.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee